EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Diabetes and hypertension are related to amyloid-beta burden in the population-based Rotterdam Study

Joyce van Arendonk iD, Julia Neitzel iD, Rebecca M E Steketee iD, Daniëlle M E van Assema, Henri A Vrooman iD, Marcel Segbers, M Arfan Ikram iD, Meike W Vernooij iD

Brain · 05.01.2023 · 146 (1) · 337-348

DOI: 10.1093/brain/awac354 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Brain, online erschienen am 12.11.2022. Verfasst von Joyce van Arendonk und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology and Nuclear Medicine, Erasmus MC, University Medical Centre, Rotterdam, The Netherlands. Hauptthemen laut MEDLINE: Alzheimer Disease, Hypercholesterolemia, Cognitive Dysfunction, Diabetes Mellitus. Die Arbeit wurde bisher 85-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Life Molecular Imaging GmbH, Erasmus Medical Center, Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Higher vascular disease burden increases the likelihood of developing dementia, including Alzheimer’s disease. Better understanding the association between vascular risk factors and Alzheimer’s disease pathology at the predementia stage is critical for developing effective strategies to delay cognitive decline. In this work, we estimated the impact of six vascular risk factors on the presence and severity of in vivo measured brain amyloid-beta (Aβ) plaques in participants from the population-based Rotterdam Study. Vascular risk factors (hypertension, hypercholesterolaemia, diabetes, obesity, physical inactivity and smoking) were assessed 13 (2004–2008) and 7 years (2009–2014) prior to 18F-florbetaben PET (2018–2021) in 635 dementia-free participants. Vascular risk factors were associated with binary amyloid PET status or continuous PET readouts (standard uptake value ratios, SUVrs) using logistic and linear regression models, respectively, adjusted for age, sex, education, APOE4 risk allele count and time between vascular risk and PET assessment. Participants’ mean age at time of amyloid PET was 69 years (range: 60–90), 325 (51.2%) were women and 190 (29.9%) carried at least one APOE4 risk allele. The adjusted prevalence estimates of an amyloid-positive PET status markedly increased with age [12.8% (95% CI 11.6; 14) in 60–69 years versus 35% (36; 40.8) in 80–89 years age groups] and APOE4 allele count [9.7% (8.8; 10.6) in non-carriers versus 38.4% (36; 40.8) to 60.4% (54; 66.8) in carriers of one or two risk allele(s)]. Diabetes 7 years prior to PET assessment was associated with a higher risk of a positive amyloid status [odds ratio (95% CI) = 3.68 (1.76; 7.61), P < 0.001] and higher standard uptake value ratios, indicating more severe Aβ pathology [standardized beta = 0.40 (0.17; 0.64), P = 0.001]. Hypertension was associated with higher SUVr values in APOE4 carriers (mean SUVr difference of 0.09), but not in non-carriers (mean SUVr difference 0.02; P = 0.005). In contrast, hypercholesterolaemia was related to lower SUVr values in APOE4 carriers (mean SUVr difference −0.06), but not in non-carriers (mean SUVr difference 0.02). Obesity, physical inactivity and smoking were not related to amyloid PET measures. The current findings suggest a contribution of diabetes, hypertension and hypercholesterolaemia to the pathophysiology of Alzheimer’s disease in a general population of older non-demented adults. As these conditions respond well to lifestyle modification and drug treatment, further research should focus on the preventative effect of early risk management on the development of Alzheimer’s disease neuropathology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseHypercholesterolemiaCognitive DysfunctionDiabetes MellitusHypertensionHumansFemaleMiddle AgedAgedAged, 80 and overMaleApolipoprotein E4Positron-Emission TomographyAmyloid beta-PeptidesBrainObesity

Stichwörter der Autor:innen

APOE4Alzheimer’s diseaseamyloid PETdiabeteshypertension

Substanzen

Apolipoprotein E4Amyloid beta-Peptides

Autor:innen und Institutionen

  • Department of Radiology and Nuclear Medicine, Erasmus MC, University Medical Centre, Rotterdam, The Netherlands.
  • Department of Epidemiology, Erasmus MC, University Medical Centre, Rotterdam, The Netherlands.
  • Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
  • Department of Medical Imaging, Nuclear Medicine, Northwest Clinics, Alkmaar, The Netherlands.

ORCID-Profile: Joyce van Arendonk, Julia Neitzel, Rebecca M E Steketee, Henri A Vrooman, M Arfan Ikram, Meike W Vernooij

Förderung

  • Life Molecular Imaging GmbH
  • Erasmus Medical Center
  • Research and Development
  • Ministry of Education, Culture and Science
  • European Commission

Zitieren

APA

van Arendonk, J., Neitzel, J., Steketee, R. M. E., van Assema, D. M. E., Vrooman, H. A., Segbers, M., Ikram, M. A., & Vernooij, M. W. (2023). Diabetes and hypertension are related to amyloid-beta burden in the population-based Rotterdam Study. Brain, 146(1), 337-348. https://doi.org/10.1093/brain/awac354

Vancouver

van Arendonk J, Neitzel J, Steketee RME, van Assema DME, Vrooman HA, Segbers M, et al. Diabetes and hypertension are related to amyloid-beta burden in the population-based Rotterdam Study. Brain. 2023;146(1):337-348. doi:10.1093/brain/awac354

BibTeX
@article{vanArendonk2023,
  author = {van Arendonk, Joyce and Neitzel, Julia and Steketee, Rebecca M E and van Assema, Daniëlle M E and Vrooman, Henri A and Segbers, Marcel and Ikram, M Arfan and Vernooij, Meike W},
  title = {Diabetes and hypertension are related to amyloid-beta burden in the population-based Rotterdam Study},
  journal = {Brain},
  year = {2023},
  volume = {146},
  number = {1},
  pages = {337--348},
  doi = {10.1093/brain/awac354}
}
Kostenlos starten →